Summary & Overview
HCPCS Level II J2777: Faricimab‑svoa Injection, 0.1 mg
Headline: HCPCS Level II code J2777 Identifies Intravitreal Faricimab‑svoa, 0.1 mg
Lead: HCPCS Level II code J2777 designates the injectable ophthalmologic drug faricimab‑svoa in 0.1 mg units for intravitreal administration. The code is central to billing for this therapy across outpatient hospitals and physician offices and affects coverage, coding workflows, and clinical billing for retina specialists nationwide.
What the code represents and why it matters: J2777 is the standardized HCPCS Level II identifier for faricimab‑svoa, enabling consistent reporting and reimbursement for intravitreal drug therapy. As a targeted treatment for retinal vascular and edema conditions, accurate use of this code ensures alignment between clinical administration and payer adjudication.
Key payers covered: The analysis encompasses major national commercial payers including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, addressing how coverage and billing practices intersect with clinical administration of intravitreal agents.
What readers will learn: The publication provides a concise coding brief that clarifies the clinical context of J2777, outlines typical sites of service and associated administration coding practices, summarizes common coverage considerations from major payers, and highlights coding connections important for billing teams and revenue cycle staff. It notes where input data is missing and flags related service codes for procedural linkage. This overview is intended for clinicians, coding professionals, and policy analysts involved in ophthalmology service lines.
Billing Code Overview
HCPCS Level II code J2777 describes the drug faricimab‑svoa, billed per 0.1 mg unit for injection. This code represents an ophthalmologic injectable therapy used in intravitreal treatment scenarios. The service type is drug administered by injection (ophthalmologic intravitreal therapy). Typical sites of service for claims including this drug are outpatient hospital settings or physician offices where intravitreal injections are performed.
Clinical & Coding Specifications
Clinical Context
A patient with decreased vision and central blurry vision presents to a retina specialist in the outpatient clinic. The ophthalmologist documents macular edema secondary to a retinal vein occlusion or other retinal edema diagnosis and determines intravitreal anti-VEGF/anti-angiopoietin therapy is indicated. The patient is counseled about intravitreal injection risks and consents. In the clinic, the patient is prepared on the procedure chair, topical anesthesia and antisepsis are applied, and intravitreal injection of faricimab‑svoa (HCPCS Level II code J2777, billed per 0.1 mg unit) is administered under sterile technique. The injection administration is reported with the intravitreal injection CPT code 67028 with the appropriate laterality modifier RT or LT appended to 67028 to indicate the treated eye. The medication drug line uses HCPCS Level II code J2777 to report the faricimab‑svoa dose supplied.
Coding Specifications
-
Modifier
RTorLT: Used to indicate Right eye (RT) or Left eye (LT) laterality when billing the administration CPT code67028. These laterality modifiers are appended to to identify which eye received the intravitreal injection. Do not append / to the HCPCS Level II code for the drug line unless payer-specific guidance requires laterality on the drug line.